Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials

References

• Molfino A, Amabile MI, Rossi Fanelli F, et al. Novel therapeutic options for cachexia and sarcopenia. Expert Opin Biol Ther. 2016;16:1239–1244.
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and precachexia: joint document elaborated by special interest groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr. 2010;29:154–159.
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Molfino A, Lucia S, et al. Cachexia: a preventable comorbidity of cancer.A T.A.R.G.E.T. approach. Crit Rev Oncol Hemat. 2015;94:251–259.
   PubMed Web of Science ®Google Scholar
• Molfino A, Amabile MI, Muscaritoli M. Nutrition support for treating cancer-associated weight loss: an update. Curr Opin Support Palliat Care. 2018;12:434–438.
   PubMed Web of Science ®Google Scholar
• Laviano A, Seelaender M, Sanchez-Lara K, et al. Beyond anorexia –cachexia. Nutrition and modulation of cancer patients’ metabolism: supplementary, complementary or alternative anti-neoplastic therapy? Eur J Pharmacol. 2011;668:S87–90.
   PubMed Web of Science ®Google Scholar
• Laviano A, Inui A, Meguid MM, et al. NPY and brain monoamines in the pathogenesis of cancer anorexia. Nutrition. 2008;24:802–805.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–495.
   PubMed Web of Science ®Google Scholar
• Baracos VE, Martin L, Korc M, et al. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105.
   PubMed Web of Science ®Google Scholar
• Aversa Z, Costelli P, Muscaritoli M. Cancer-induced muscle wasting: latest findings in prevention and treatment. Ther Adv Med Oncol. 2017;9:369–382.
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Rossi Fanelli F, Molfino A. Perspectives of health care professionals on cancer cachexia: results from three global surveys. Ann Oncol. 2016;27:2230–2236.
   PubMed Web of Science ®Google Scholar
• Madeddu C, Mantovani G, Gramignano G, et al. Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. Future Oncol. 2015;11:2697–2710.
   PubMed Web of Science ®Google Scholar
• Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16:153–166.
   PubMed Web of Science ®Google Scholar
• Garcia JM. What is next after anamorelin? Curr Opin Support Palliat Care. 2017;11:266–271.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Macciò A, Madeddu C, et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl). 2010;88:85–92.
   PubMed Web of Science ®Google Scholar
• Currow DC, Maddocks M, Cella D, et al. Efficacy of anamorelin, a novel non-peptide ghrelin analogue, in patients with advanced non-small cell lung cancer (NSCLC) and cachexia-review and expert opinion. Int J Mol Sci. 2018;19(11):pii: E3471.
   PubMed Web of Science ®Google Scholar
• Currow DC, Abernethy AP. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol. 2014;10:789–802.
   PubMed Web of Science ®Google Scholar
• Zhang H, Garcia JM. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother. 2015;16:1245–1253.
   PubMed Web of Science ®Google Scholar
• Laviano A, Molfino A, Rianda S, et al. The growth hormone secretagogue receptor (Ghs-R). Curr Pharm Des. 2012;18:4749–4754.
   PubMed Web of Science ®Google Scholar
• Garcia JM, Polvino WJ. Effect on body weight and safety of rc-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase i, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist. 2007;12:594–600.
   PubMed Web of Science ®Google Scholar
• Garcia JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16:108–116.
   PubMed Web of Science ®Google Scholar
• Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519–531.
   PubMed Web of Science ®Google Scholar
• Currow D, Temel JS, Abernethy A, et al. ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia. Ann Oncol. 2017;28:1949–1956.
   PubMed Web of Science ®Google Scholar
• Dingemans AM, de Vos-Geelen J, Langen R, et al. Phase II drugs that are currently in development for the treatment of cachexia. Expert Opin Investig Drugs. 2014;23:1655–1669.
   PubMed Web of Science ®Google Scholar
• Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab. 2001;86:5108–5117.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Calof OM, Storer TW, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006;2:146–159.
   PubMedGoogle Scholar
• Wright TJ, Dillon EL, Durham WJ, et al. A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women. J Cachexia Sarcopenia Muscle. 2018;9:482–496.
   PubMed Web of Science ®Google Scholar
• Narayanan R, Coss CC, Yepuru M, et al. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol. 2008;22:2448–2465.
   PubMed Web of Science ®Google Scholar
• Crawford J, Prado CM, Johnston M, et al. Study design and rationale for the phase 3 clinical development program of Enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials). Curr Oncol Rep. 2016;18:37.
   PubMed Web of Science ®Google Scholar
• Last accessed July 22, 2019. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01355484
   Google Scholar
• Srinath R, Dobs A. Enobosarm (gtx-024, s-22): a potential treatment for cachexia. Future Oncol. 2014;10:187-194.
   PubMed Web of Science ®Google Scholar
• Chasen M, Hirschman SZ, Bhargava R. Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J Am Med Dir Assoc. 2011;12:62–67.
   PubMed Web of Science ®Google Scholar
• Yennurajalingam S, Willey JS, Palmer JL, et al. The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J Palliat Med. 2012;15:1059–1064.
   PubMed Web of Science ®Google Scholar
• Wilkes EA, Selby AL, Cole AT, et al. Poor tolerability of thalidomide in end-stage oesophageal cancer. Eur J Cancer Care (Engl). 2011;20:593–600.
   PubMed Web of Science ®Google Scholar
• Khan ZH, Simpson EJ, Cole AT, et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther. 2003;17:677–682.
   PubMed Web of Science ®Google Scholar
• Rigas JR, Schuster M, Orlov SV, et al. Effect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial. J Clin Oncol. 2010;28:S7622.
   Web of Science ®Google Scholar
• Jatoi A, Ritter HL, Dueck A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. 2010;68:234–239.
   PubMed Web of Science ®Google Scholar
• Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15:656–666.
   PubMed Web of Science ®Google Scholar
• Hong DS, Janku F, Naing A, et al. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015;33:621–631.
   PubMed Web of Science ®Google Scholar
• Hickish T, Andre T, Wyrwicz L, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2017;18:192–201.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Y, Tong M, et al. New prospect for cancer cachexia: medical cannabinoid. J Cancer. 2019;10:716–720.
   PubMed Web of Science ®Google Scholar
• Brisbois TD, de Kock IH, Watanabe SM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011;22:2086–2093.
   PubMed Web of Science ®Google Scholar
• Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D, et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018;26:3029–3038.
   PubMed Web of Science ®Google Scholar
• Cote M, Trudel M, Wang C, et al. Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Ann Otol Rhinol Laryngol. 2016;125:317–324.
   PubMed Web of Science ®Google Scholar
• Laviano A, Molfino A, Seelaender M, et al. Carnitine administration reduces cytokine levels, improves food intake, and ameliorates body composition in tumor-bearing rats. Cancer Invest. 2011;29:696–700.
   PubMed Web of Science ®Google Scholar
• Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36:11–48.
   PubMed Web of Science ®Google Scholar
• Molfino A, Amabile MI, Monti M, et al. Carnitine for the treatment of cachexia: lights and shadows. Int J Cardiol. 2015;198:180–181.
   PubMed Web of Science ®Google Scholar
• Molfino A, Amabile MI, Monti M, et al. Omega-3 polyunsaturated fatty acids in critical illness: anti-inflammatory, proresolving, or both? Oxid Med Cell Longev. 2017;2017:5987082.
   PubMed Web of Science ®Google Scholar
• Di Girolamo FG, Situlin R, Mazzucco S, et al. Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia. Curr Opin Clin Nutr Metab Care. 2014;17:145–150.
   PubMed Web of Science ®Google Scholar
• Smith GI, Atherton P, Reeds DN, et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr. 2011;93:402–412.
   PubMed Web of Science ®Google Scholar
• Laviano A, Rianda S, Molfino A, et al. Omega-3 fatty acids in cancer. Curr Opin Clin Nutr Metab Care. 2013;16:156–161.
   PubMed Web of Science ®Google Scholar
• Pottel L, Lycke M, Boterberg T, et al. Echium oil is not protective against weight loss in head and neck cancer patients undergoing curative radio(chemo)therapy: a randomised-controlled trial. BMC Complement Altern Med. 2014;14:382.
   PubMed Web of Science ®Google Scholar
• Burns CP, Halabi S, Clamon G, et al. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer. 2004;101:370–378.
   PubMed Web of Science ®Google Scholar
• Sánchez-Lara K, Turcott JG, Juárez-Hernández E, et al. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. Clin Nutr. 2014;33:1017–1023.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Macciò A, Madeddu C, et al. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev. 2006;15:1030–1034.
   PubMed Web of Science ®Google Scholar
• Kapoor N, Naufahu J, Tewfik S, et al. A prospective randomized controlled trial to study the impact of a nutrition-sensitive intervention on adult women with cancer cachexia undergoing palliative care in India. Integr Cancer Ther. 2017;16:74–84.
   PubMed Web of Science ®Google Scholar
• Stewart Coats AJ, Ho GF, Prabhash K, et al. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016;7:355–365.
   PubMed Web of Science ®Google Scholar
• Greig CA, Johns N, Gray C, et al. Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy. Support Care Cancer. 2014;22:1269–1275.
   PubMed Web of Science ®Google Scholar
• Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer. 2008;44:1124–1132.
   PubMed Web of Science ®Google Scholar
• Balstad TR, Kaasa S, Solheim TS. Multimodal nutrition/anabolic therapy for wasting conditions. Curr Opin Clin Nutr Metab Care. 2014;17(3):226–235.
   PubMed Web of Science ®Google Scholar
• Argiles JM, Busquets S, López-Soriano FJ, et al. Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle. 2012;3:73–76.
   PubMed Web of Science ®Google Scholar
• Solheim TS, Laird BJA, Balstad TR, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017;8:778–788.
   PubMed Web of Science ®Google Scholar
• Solheim TS, Laird BJA, Balstad TR, et al. Cancer cachexia: rationale for the MENAC (Multimodal-exercise, nutrition and anti-inflammatory medication for Cachexia) trial. BMJ Support Palliat Care. 2018;8:258–265.
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Molfino A, Gioia G, et al. The “parallel pathway”: a novel nutritional and metabolic approach to cancer patients. Intern Emerg Med. 2011;6:105–112.
   PubMed Web of Science ®Google Scholar
• Rohm M, Zeigerer A, Machado J, et al. Energy metabolism in cachexia. EMBO Rep. 2019;20:pii: e47258.
   PubMed Web of Science ®Google Scholar
• Madeddu C, Dessì M, Panzone F, et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr. 2012;31:176–182.
   PubMed Web of Science ®Google Scholar
• Macciò A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol. 2012;124:417–425.
   PubMed Web of Science ®Google Scholar